Research ExplorerPublicationsIntermediate prognosis in metastatic germ cell tumours-outco...

Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors

Standard

Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors. / Seidel, Christoph; Daugaard, Gedske; Tryakin, Alexey; Necchi, Andrea; Cohn Cedermark, Gabriella; Ståhl, Olof; Hentrich, Marcus; Brito, Margarida; Albany, Costantine; Taza, Fadi; Gerl, Arthur; Oechsle, Karin; Bokemeyer, Carsten.

In: EUR J CANCER, Vol. 94, 05.2018, p. 16-25.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Seidel, C, Daugaard, G, Tryakin, A, Necchi, A, Cohn Cedermark, G, Ståhl, O, Hentrich, M, Brito, M, Albany, C, Taza, F, Gerl, A, Oechsle, K & Bokemeyer, C 2018, 'Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors', EUR J CANCER, vol. 94, pp. 16-25. https://doi.org/10.1016/j.ejca.2018.01.113

APA

Seidel, C., Daugaard, G., Tryakin, A., Necchi, A., Cohn Cedermark, G., Ståhl, O., Hentrich, M., Brito, M., Albany, C., Taza, F., Gerl, A., Oechsle, K., & Bokemeyer, C. (2018). Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors. EUR J CANCER, 94, 16-25. https://doi.org/10.1016/j.ejca.2018.01.113

Vancouver

Seidel C, Daugaard G, Tryakin A, Necchi A, Cohn Cedermark G, Ståhl O et al. Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors. EUR J CANCER. 2018 May;94:16-25. https://doi.org/10.1016/j.ejca.2018.01.113

Bibtex

@article{6e9dd3149ae742e6b36bed3bae3c0e16,
title = "Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors",
abstract = "BACKGROUND: For metastatic germ cell tumour patients with intermediate prognosis (IPGCT) according to the IGCCCG classification 5-year overall survival (OS) rates of 79% were described, but recent data suggest significant changes.PATIENTS AND METHODS: To compare the outcome of current IPGCT with former patients and to find new prognosticators a retrospective observational study was performed. Eligibility criteria were: age ≥16 years, diagnosed between 1979 and 2014. Primary end-point was the 5-year OS rate.RESULTS: This database includes 707 IPGCT: group 1 was diagnosed 1979-1996 (n = 237), and group 2 1997-2014 (n = 470). Median follow-up was 8.6 years (IQR: 14.4). Group 1 and 2 received first-line treatment with BEP (median 4 cycles; range 1-6) in 99% (group 1) and 95% (group 2), respectively. The proportion of first-line chemotherapy responders (CR and marker negative PR) was similar: 94% (group 1) and 96% (group 2), respectively (P = 0.290), but OS was superior in group 2 with a 5-year OS rate of 89% compared with 83% in group 1 (P = 0.035). In refractory disease, high-dose chemotherapy and treatment beyond second line was performed more often in group 2. A lactate dehydrogenase (LDH) cut-off value of 2 ULN (P = 0.002; HR 2.121) and alpha-fetoprotein (AFP) levels of 6200 IU/ml (P = 0.032; HR 2.155) pre-chemotherapy were independent prognosticators for OS in a multivariate analysis.CONCLUSION: Outcome of IPGCT has improved and is now closer to the good prognosis category. LDH and AFP levels represent potential markers to stratify IPGCT before treatment initiation.",
keywords = "Journal Article",
author = "Christoph Seidel and Gedske Daugaard and Alexey Tryakin and Andrea Necchi and {Cohn Cedermark}, Gabriella and Olof St{\aa}hl and Marcus Hentrich and Margarida Brito and Costantine Albany and Fadi Taza and Arthur Gerl and Karin Oechsle and Carsten Bokemeyer",
note = "Copyright {\textcopyright} 2018 Elsevier Ltd. All rights reserved.",
year = "2018",
month = may,
doi = "10.1016/j.ejca.2018.01.113",
language = "English",
volume = "94",
pages = "16--25",
journal = "EUR J CANCER",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

RIS

TY - JOUR

T1 - Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors

AU - Seidel, Christoph

AU - Daugaard, Gedske

AU - Tryakin, Alexey

AU - Necchi, Andrea

AU - Cohn Cedermark, Gabriella

AU - Ståhl, Olof

AU - Hentrich, Marcus

AU - Brito, Margarida

AU - Albany, Costantine

AU - Taza, Fadi

AU - Gerl, Arthur

AU - Oechsle, Karin

AU - Bokemeyer, Carsten

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2018/5

Y1 - 2018/5

N2 - BACKGROUND: For metastatic germ cell tumour patients with intermediate prognosis (IPGCT) according to the IGCCCG classification 5-year overall survival (OS) rates of 79% were described, but recent data suggest significant changes.PATIENTS AND METHODS: To compare the outcome of current IPGCT with former patients and to find new prognosticators a retrospective observational study was performed. Eligibility criteria were: age ≥16 years, diagnosed between 1979 and 2014. Primary end-point was the 5-year OS rate.RESULTS: This database includes 707 IPGCT: group 1 was diagnosed 1979-1996 (n = 237), and group 2 1997-2014 (n = 470). Median follow-up was 8.6 years (IQR: 14.4). Group 1 and 2 received first-line treatment with BEP (median 4 cycles; range 1-6) in 99% (group 1) and 95% (group 2), respectively. The proportion of first-line chemotherapy responders (CR and marker negative PR) was similar: 94% (group 1) and 96% (group 2), respectively (P = 0.290), but OS was superior in group 2 with a 5-year OS rate of 89% compared with 83% in group 1 (P = 0.035). In refractory disease, high-dose chemotherapy and treatment beyond second line was performed more often in group 2. A lactate dehydrogenase (LDH) cut-off value of 2 ULN (P = 0.002; HR 2.121) and alpha-fetoprotein (AFP) levels of 6200 IU/ml (P = 0.032; HR 2.155) pre-chemotherapy were independent prognosticators for OS in a multivariate analysis.CONCLUSION: Outcome of IPGCT has improved and is now closer to the good prognosis category. LDH and AFP levels represent potential markers to stratify IPGCT before treatment initiation.

AB - BACKGROUND: For metastatic germ cell tumour patients with intermediate prognosis (IPGCT) according to the IGCCCG classification 5-year overall survival (OS) rates of 79% were described, but recent data suggest significant changes.PATIENTS AND METHODS: To compare the outcome of current IPGCT with former patients and to find new prognosticators a retrospective observational study was performed. Eligibility criteria were: age ≥16 years, diagnosed between 1979 and 2014. Primary end-point was the 5-year OS rate.RESULTS: This database includes 707 IPGCT: group 1 was diagnosed 1979-1996 (n = 237), and group 2 1997-2014 (n = 470). Median follow-up was 8.6 years (IQR: 14.4). Group 1 and 2 received first-line treatment with BEP (median 4 cycles; range 1-6) in 99% (group 1) and 95% (group 2), respectively. The proportion of first-line chemotherapy responders (CR and marker negative PR) was similar: 94% (group 1) and 96% (group 2), respectively (P = 0.290), but OS was superior in group 2 with a 5-year OS rate of 89% compared with 83% in group 1 (P = 0.035). In refractory disease, high-dose chemotherapy and treatment beyond second line was performed more often in group 2. A lactate dehydrogenase (LDH) cut-off value of 2 ULN (P = 0.002; HR 2.121) and alpha-fetoprotein (AFP) levels of 6200 IU/ml (P = 0.032; HR 2.155) pre-chemotherapy were independent prognosticators for OS in a multivariate analysis.CONCLUSION: Outcome of IPGCT has improved and is now closer to the good prognosis category. LDH and AFP levels represent potential markers to stratify IPGCT before treatment initiation.

KW - Journal Article

U2 - 10.1016/j.ejca.2018.01.113

DO - 10.1016/j.ejca.2018.01.113

M3 - SCORING: Journal article

C2 - 29505967

VL - 94

SP - 16

EP - 25

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

ER -